MMP-13 selective α-sulfone hydroxamates: A survey of P1′ heterocyclic amide isosteres
摘要:
Seeking compounds preferentially potent and selective for MMP-13, we reported in the preceding Letter on a series of hydroxamic acids with a flexible benzamide tail groups. (1a) Here, we replace the amide moiety with non-hydrolyzable heterocycles in an effort to improve half-life. We identify a hydroxamate tetrazole 4e that spares MMP-1 and -14, shows >400-fold selectivity versus MMP-8 and >600-fold selectivity versus MMP-2, and has a 4.8 h half-life in rats. X-ray data (1.9 angstrom) for tetrazole 4c is presented. (C) 2011 Elsevier Ltd. All rights reserved.
The present invention relates to a class of EP2 antagonistazetidines of general formula (I), wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in the treatment of endometriosis and/or uterine fibroids (leiomyomata) and to intermediates usefulin their synthesis and to compositions containing them.
Aromatic sulfone hydroxamates and their use as protease inhibitors
申请人:——
公开号:US20040010019A1
公开(公告)日:2004-01-15
This invention is directed to aromatic sulfone hydroxamates (also known as “aromatic sulfone hydroxamic acids”) and salts thereof that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to a prevention or treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP and/or aggrecanase activity.
MMP-13 selective α-sulfone hydroxamates: A survey of P1′ heterocyclic amide isosteres
作者:Thomas E. Barta、Daniel P. Becker、Louis J. Bedell、Alan M. Easton、Susan L. Hockerman、James Kiefer、Grace E. Munie、Karl J. Mathis、Madeleine H. Li、Joseph G. Rico、Clara I. Villamil、Jennifer M. Williams
DOI:10.1016/j.bmcl.2011.03.099
日期:2011.5
Seeking compounds preferentially potent and selective for MMP-13, we reported in the preceding Letter on a series of hydroxamic acids with a flexible benzamide tail groups. (1a) Here, we replace the amide moiety with non-hydrolyzable heterocycles in an effort to improve half-life. We identify a hydroxamate tetrazole 4e that spares MMP-1 and -14, shows >400-fold selectivity versus MMP-8 and >600-fold selectivity versus MMP-2, and has a 4.8 h half-life in rats. X-ray data (1.9 angstrom) for tetrazole 4c is presented. (C) 2011 Elsevier Ltd. All rights reserved.